clonidine · Rosemount · NDA 022500
Nexiclon Xr
Earliest generic entry, as listed · earliest of 2 marketed strengths
8 Sep 2031
No marketed reference-listed strength; date taken from all listed strengths.
Blocked by patent: US 8623409.
Listed patents · 2 unexpired
| Patent | Claims | Expires |
|---|---|---|
| US 8623409 | drug product · sets the listed date | 8 Sep 2031 |
| US 8337890 | drug product | 17 Apr 2027 |
Exclusivities · 0 unexpired
No unexpired exclusivities listed.
Paragraph IV certifications · 0
No Paragraph IV certification listed by FDA for this drug.
The list shows that a generic applicant certified to FDA that a listed patent is invalid or not infringed. It does not show litigation, settlements or launch timing.
Event history
No events yet. The first ingestion only records products entering their 12-month window; changes appear from the next Orange Book update.
Products covered · 2
| NDA · product | Form | Strength | Listed expiry |
|---|---|---|---|
| 022500 · 001 | tablet, extended release, oral | EQ 0.17MG BASE | 8 Sep 2031 |
| 022500 · 002 · discontinued | tablet, extended release, oral | EQ 0.26MG BASE | 8 Sep 2031 |